Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy [0.03%]
利尤单抗低剂量（40毫克）治疗复发和难治性经典霍奇金淋巴瘤的5年随访：与标准剂量治疗队列相匹配的研究
Liudmila Fedorova,Kirill Lepik,Polina Kotselyabina et al.
Liudmila Fedorova et al.
The use of low-dose PD-1 inhibitors may offer a promising treatment strategy for patients with refractory Hodgkin lymphoma. This approach has the potential to mitigate the financial toxicity commonly associated with immune checkpoint inhibi...
Tissue-Equivalents of Lymphoid Clonal Hematopoiesis of Indeterminate Potential (L-CHIP) and Germline-Derived Lymphoproliferations: Possible Caveats for Hematopathologists [0.03%]
淋巴克隆不确定潜能的淋巴组织等同物和由胚系衍生的淋巴增殖性病变：血液病理学家应注意的问题
Magdalena M Brune,Ivana Bratic Hench,Stefan Dirnhofer et al.
Magdalena M Brune et al.
Clonal hematopoiesis of indeterminate potential (CHIP) is a predisposing condition to lymphoma development. CHIP carrying mutations that are recurrently found in lymphomas are designated as L-CHIP. We presume that bone marrow-derived L-CHIP...
Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective [0.03%]
意大利观点下的复发/难治性滤泡淋巴瘤的治疗综述
Giacomo Loseto,Maria Chiara Tisi,Antonella Anastasia et al.
Giacomo Loseto et al.
Follicular lymphoma (FL) is an indolent disease characterized by multiple relapses and eventual refractoriness to therapy. Despite advancements in therapeutic approaches, FL treatment algorithm and management remain not well-established, ne...
Routine Monitoring of CAR-T-Cells Expansion and Persistence in Patients With Aggressive Large B-Cell Lymphoma by Flow Cytometry: A Single-Center Experience [0.03%]
流式细胞仪监测弥漫大B细胞淋巴瘤患者接受CAR-T细胞治疗后的扩增及持久性：一项单中心经验报告
Alexandra Zduniak,Jérémie Martinet,Emilie Lévêque et al.
Alexandra Zduniak et al.
This retrospective, single-center study evaluated routine flow cytometry (FC) monitoring of CAR-T-cells in 45 patients with aggressive large B-cell lymphoma (LBCL). CAR-T-cells expansion was assessed from Day 0 to Month 12. Peak expansion o...
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort [0.03%]
基于自我报告的Charlson共病指数在淋巴瘤流行病学结局队列中的适用性及性能评估研究
James R Cerhan,Tereza Sokolova,Elliott J Cahn et al.
James R Cerhan et al.
Newly diagnosed patients with non-Hodgkin lymphoma (NHL) often have a history of other diseases, and these comorbidities can impact patient treatment and management options, as well as overall survival (OS). We developed the Lymphoma Epidem...
A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection [0.03%]
CAR-T细胞治疗滤泡性淋巴瘤的SWOT-共识：优化患者旅程和选择riteria
Monia Marchetti,Paolo Corradini,Luca Arcaini et al.
Monia Marchetti et al.
Over the past 2 decades, advancements in follicular lymphoma (FL) treatment, particularly with anti-CD20 antibodies, have significantly improved patient survival. However, a subset of FL patients experiences early relapse and progression wi...
Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi-Omic Analysis [0.03%]
凋亡细胞清除与M2型巨噬细胞极化基因表达与复发及难治性经典霍奇金淋巴瘤相关性的多组学分析
Juan Quarroz Braghini,María Cecilia Cabral Lorenzo,Laura Kornblihtt et al.
Juan Quarroz Braghini et al.
Classical Hodgkin Lymphoma (cHL) exhibits rare malignant Hodgkin-Reed Sternberg (HRS) cells within a reactive immune microenvironment. This study developed an HRS cell gene expression signature to identify HRS cells in single-cell RNA seque...
Treatment-related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase-based regimens: A multicenter electronic health research network study [0.03%]
接受聚甘露糖酶基方案治疗的成人胡尼索特急性淋巴细胞白血病患者的治疗方法相关的毒性差异：一项多中心电子健康研究网络研究
Benjamin J Lee,Shawn P Griffin
Benjamin J Lee
Prognostic Value of C-Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma [0.03%]
allo-HSCT前C-反应蛋白血小板比值可作为淋巴瘤预后的标志物
Akihiko Izumi,Takayoshi Tachibana,Hiroto Ishii et al.
Akihiko Izumi et al.
Previous studies have shown that the pre-transplant C-reactive protein (CRP)/platelet ratio (CP ratio) is a predictor of survival. The aim of this multicenter retrospective study was to evaluate the clinical significance of CP ratio in pati...
Multicenter Study
Hematological oncology. 2025 Sep;43(5):e70136. DOI:10.1002/hon.70136 2025